ONCY
NASDAQOncolytics Biotech Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks103-50%
2026-03-012026-08-23
Mix3190d
- Insider16(52%)
- SEC Filings9(29%)
- Other5(16%)
- Leadership1(3%)
Latest news
25 items- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal CancerFDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that it has received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033,
- SECSEC Form 10-Q filed by Oncolytics Biotech Inc.10-Q - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal CancerDesignation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics’ regulatory momentum and continues to advance the Company’s path toward registration SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of p
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer TrialHalf of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design Part B will be a randomized study designed to support potential accelerated and full approval SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key in
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expans
- INSIDERSEC Form 3 filed by new insider Mcadory John Bearden3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Pisano Wayne4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Rigby Jonathan4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Holtham Angela4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Parsons James T.4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Aromando Andrew4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Look Kirk4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Kelly Jared4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 3 filed by new insider Glover Stephen C.3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Andrews Patricia S4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Seizinger Bernd R.4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Hagerman Allison4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Glover Stephen C.4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Brown Deborah Margaret4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
ONCY FAQ
6 questionsWhat does Oncolytics Biotech Inc. do?
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC...Where does ONCY stock trade?
Oncolytics Biotech Inc. (ONCY) is listed on NASDAQ.What sector and industry is ONCY in?
Oncolytics Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ONCY?
Oncolytics Biotech Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $700.00 price target on 2025-08-13. Recent price targets range from $300.00 to $700.00.What companies are similar to ONCY?
Notable peers in the same industry include LEGN (Legend Biotech Corporation), PBYI (Puma Biotechnology Inc), FBIO (Fortress Biotech Inc.), MBRX (Moleculin Biotech Inc.). Compare ONCY side-by-side with any of them on Quantisnow.How can I track ONCY on Quantisnow?
Quantisnow aggregates Oncolytics Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONCY to receive live email and push alerts on every new disclosure.